Adenomatous polyposis coli protein (APC)

Adenomatous polyposis coli protein (APC) is a large multidomain tumor suppressor crucial for intestinal epithelial homeostasis and a central negative regulator of canonical Wnt/β-catenin signaling[1][2][3][5][8]. APC acts as a scaffold in the β-catenin destruction complex (along with Axin, GSK3β, CK1), which targets β-catenin for proteasomal degradation, thus downregulating Wnt signaling and controlling cell proliferation, differentiation, division, adhesion, and migration[2][3][8]. APC also has critical roles in organizing cell polarity, regulating cytoskeleton dynamics (actin and microtubules), and maintaining epithelial integrity[7][10]. Mutations or truncations in APC disable its destruction complex function, leading to unregulated β-catenin–driven gene transcription, excessive cell proliferation, and malignancy, especially in colorectal cancer and familial adenomatous polyposis[1][4][6][9]. Although APC itself is not directly targeted by clinical drugs, its status is used as a biomarker and therapeutic approaches often aim at downstream effects or restoration of Wnt pathway regulation[4][9]. The complexity of APC’s functions in cell biology and cancer makes it an important target for research, but direct pharmacological targeting remains challenging due to widespread and pleiotropic roles as a tumor suppressor and cytoskeletal anchor[5][10].

Other names

APCProtein APCDP2.5DP2DP3PPP1R46BTPS2DESMDDeleted in polyposis 2.5Epididymis secretory sperm binding proteinWnt signaling pathway regulatorAdenomatous polyposis coli tumor suppressorProtein phosphatase 1 regulatory subunit 46

Most drugs in development aim to inhibit the Wnt/β-catenin pathway, often through stabilization or degradation of β-catenin—by mimicking or restoring APC function Some drug concepts involve reactivation of APC activity or targeting downstream effects of APC loss